SCHEMBL7780561

SCHEMBL7780561

Nc1cc(F)c(Cl)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.45
TP53 P04637 1/20 0.45
ALDH1A1 P00352 4/20 0.43
THRB P10828 1/20 0.39
TSHR P16473 2/20 0.33
GAA P10253 2/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
KHK P50053 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1041423 0.86 CYP3A4 (0.39) CYP3A4TP53ALDH1A1THRBGAA
SCHEMBL31246242 0.86 CYP3A4 (0.50) CYP3A4TP53ALDH1A1THRBTSHR
SCHEMBL17964095 0.86 CYP3A4 (0.50) CYP3A4TP53ALDH1A1THRBTSHR
SCHEMBL23205851 0.82 CYP3A4 (0.38) CYP3A4TP53ALDH1A1THRBTSHR
SCHEMBL21050751 0.82 GAA (0.46) CYP3A4TP53ALDH1A1THRBGAA
SCHEMBL30103861 0.77 GAA (0.41) CYP3A4ALDH1A1TSHRGAAMAPT
SCHEMBL24952849 0.77 GAA (0.41) CYP3A4ALDH1A1TSHRGAAMAPT
SCHEMBL20045612 0.75 CYP3A4 (0.50) CYP3A4TP53ALDH1A1THRBTSHR
SCHEMBL8374401 0.75 CA1 (0.37) CYP3A4TP53ALDH1A1GAACA1
SCHEMBL30005190 0.75 CYP3A4 (0.50) CYP3A4TP53ALDH1A1THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
EP-4729510-A1 INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Suzhou Merna Therapeutics Co. Ltd (CN) 2026-04-22 EP disclosed
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY (US) 2025-11-20 US disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 EP disclosed
US-20250320224-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2025-10-16 US disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
US-12319698-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2025-06-03 US disclosed
CN-119894869-A Substituted biaryl kadetoxin-like quinolones having enhanced antiparasitic activity 俄勒冈健康与科学大学 2025-04-25 CN disclosed
EP-4536639-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY Oregon Health & Science University (US) 2025-04-16 EP disclosed
EP-4532496-A1 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2025-04-09 EP disclosed
US-9120788-B2 Azabenzimidazole compounds PFIZER INC. (US) 2015-09-01 US disclosed
WO-2014128585-A1 AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER INC. (US) 2014-08-28 WO disclosed
WO-2014128585-A1 AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER INC. (US) 2014-08-28 WO disclosed
US-20140235612-A1 Azabenzimidazole Compounds PFIZER (US) 2014-08-21 US disclosed
US-20140235612-A1 Azabenzimidazole Compounds PFIZER (US) 2014-08-21 US disclosed
US-20140235612-A1 Azabenzimidazole Compounds PFIZER (US) 2014-08-21 US disclosed
EP-0637623-B1 Cyclic hydrocarbon derivative and liquid crystal composition containing the same DAINIPPON INK & CHEMICALS (JP) 2001-10-04 EP disclosed
US-5536443-A DUTERIUM CONTAINING COMPOUNDS FOOR ELECTROOPTICAL APPARATUS DAINIPPON INK & CHEMICALS, INC. (JP) 1996-07-16 US disclosed
US-5474707-A Electrooptic display DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-12-12 US disclosed
EP-0637623-A1 Cyclic hydrocarbon derivative and liquid crystal composition containing the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1995-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 CYP3A4 64/4885TP53 3791/4885ALDH1A1 87/4885
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY EPX, TFEB, EPHX1 CYP3A4 451/4885TP53 4548/4885ALDH1A1 2498/4885
US-12319698-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 CYP3A4 2972/4885TP53 316/4885ALDH1A1 3438/4885
US-20250320224-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 CYP3A4 888/4885TP53 4127/4885ALDH1A1 1534/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI CYP3A4 303/4885TP53 7/4885ALDH1A1 63/4885
US-20140235612-A1 Azabenzimidazole Compounds AZI2, HDAC6, ABL1 CYP3A4 42/4885TP53 1091/4885ALDH1A1 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.